Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The State of SLIT

The State of SLIT EDITORIAL Johannes Ring (Executive Editor) Lanny Rosenwasser (Editor-in-Chief) s was noted in last month’s editorial, significant progress has been made in the past year Ain many aspects of Allergy and Immunology worldwide, especially in areas that are spearheaded by WAO. One of the critical aspects of our discipline is the use of allergen specific immuno- therapy as treatment for allergic diseases. Originally, the empiric institution of this therapy was found to have profound influences on diseases such as allergic catarrh or hay fever. The current state of the art has been reviewed in many venues, and significant information over the past 20 years has accumulated that a particular route of administering immunotherapy, namely sublingual immunotherapy (SLIT), has a particularly strong profile in terms of safety without sacrificing the usual efficacy associated with standard injection subcuta- neous immunotherapy (SCIT). Potential mechanisms to underline this approach to specific immunotherapy include the route of mucosal administration as being a particularly effective form of inducing immune tolerance without some of the potential risks of parenteral administration. The allergy diagnosis, the indication, initiation, and follow-up observation of SLIT is the absolute domain of an experienced allergist. The WAO has taken a significant interest in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png World Allergy Organization Journal Springer Journals

Loading next page...
 
/lp/springer-journals/the-state-of-slit-pjtcneV0Ld

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2009 by World Allergy Organization; licensee BioMed Central Ltd.
Subject
Medicine & Public Health; Allergology; Immunology
eISSN
1939-4551
DOI
10.1097/WOX.0b013e3181954066
pmid
23282886
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Johannes Ring (Executive Editor) Lanny Rosenwasser (Editor-in-Chief) s was noted in last month’s editorial, significant progress has been made in the past year Ain many aspects of Allergy and Immunology worldwide, especially in areas that are spearheaded by WAO. One of the critical aspects of our discipline is the use of allergen specific immuno- therapy as treatment for allergic diseases. Originally, the empiric institution of this therapy was found to have profound influences on diseases such as allergic catarrh or hay fever. The current state of the art has been reviewed in many venues, and significant information over the past 20 years has accumulated that a particular route of administering immunotherapy, namely sublingual immunotherapy (SLIT), has a particularly strong profile in terms of safety without sacrificing the usual efficacy associated with standard injection subcuta- neous immunotherapy (SCIT). Potential mechanisms to underline this approach to specific immunotherapy include the route of mucosal administration as being a particularly effective form of inducing immune tolerance without some of the potential risks of parenteral administration. The allergy diagnosis, the indication, initiation, and follow-up observation of SLIT is the absolute domain of an experienced allergist. The WAO has taken a significant interest in

Journal

World Allergy Organization JournalSpringer Journals

Published: Jan 15, 2009

There are no references for this article.